Cypre

Cypre is a biotechnology company dedicated to overcoming treatment resistance in cancer patients. By combining its professional translation technology and patented Falcon-X™ 3D tumor model platform, Cypre has driven new insights into the tumor microenvironment and predicted the efficacy of targeted drugs and immunotherapy, focusing on improving cancer treatments and patient immunotherapy—from drug discovery to clinical applications. We are now applying this approach with strategic partners for therapeutic discovery, lead validation, and precision medicine, utilizing the platform for drug discovery and precision healthcare.